Recombinant Human HLA-A*02:01&B2M&CMV pp65(NLVPMVATV) Monomer Protein (HEK293)，Avi & His

The study of the HLA-A*02:01/B2M/CMV pp65 (NLVPMVATV) monomeric recombinant protein is critical in understanding immune responses to cytomegalovirus (CMV) infection, particularly in individuals with HLA-A*02:01 alleles, which are prevalent in various populations. CMV is a significant viral pathogen known to cause severe disease in immunocompromised patients, such as organ transplant recipients and those with HIV/AIDS. The pp65 protein is a major immunodominant antigen for CD8+ T cell responses in CMV infection. By developing a recombinant protein that includes the HLA-A*02:01 molecule, β2-microglobulin (B2M), and the specific epitope NLVPMVATV from CMV pp65, researchers can create a model to study the binding affinity, T cell receptor recognition, and overall immune response. This monomeric complex facilitates detailed immunological studies that can enhance our understanding of protective immunity against CMV. Furthermore, by evaluating how these components interact, scientists aim to inform vaccine development strategies, enhance the design of adoptive T cell therapies, and ultimately improve clinical outcomes for patients at risk of CMV-related diseases. The integration of structural biology and immunology in this research area underscores its potential to translate findings into therapeutic advances and improve management of CMV in vulnerable populations. As CMV remains a major challenge in clinical settings, this recombinant protein research is pivotal for enhancing our knowledge of T cell-mediated immune responses and facilitating effective interventions.